Artal Group’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Artal Group’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-350,000	Closed	-$17M	–	111
2019 Q3	$17M	Buy	+350,000	New	+$18.2M	0.68%	28
2018 Q3	–	Sell	-200,000	Closed	-$9.04M	–	120
2018 Q2	$9.04M	Hold	200,000	–	–	0.19%	49
2018 Q1	$9.66M	Sell	200,000 -150,000	-43%	-$8.37M	0.12%	48
2017 Q4	$13.8M	Buy	350,000 +50,000	+17%	+$1.87M	0.21%	40
2017 Q3	$9.31M	Buy	300,000 +200,000	+200%	+$5.62M	0.16%	46
2017 Q2	$2.73M	Sell	100,000 -75,000	-43%	-$2.23M	0.05%	85
2017 Q1	$6.45M	Sell	175,000 -71,054	-29%	-$1.79M	0.14%	53
2016 Q4	$3.56M	Buy	246,054 +146,054	+146%	+$2.57M	0.08%	64
2016 Q3	$2.31M	Sell	100,000 -25,000	-20%	-$476K	0.05%	82
2016 Q2	$2.07M	Buy	+125,000	New	+$2.52M	0.04%	58

Other funds holding GBT

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Artal Group's GBT Position: Q4 2019 in Review

Artal Group sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2019, closing a stake of 350,000 shares — an estimated $17M sold.

Artal Group first reported a position in GBT in Q2 2016 and held it in 10 quarters. The position peaked at $17M in Q3 2019. 234 funds tracked by Wall St. Rank hold GBT as of Q4 2019.

Artal Group reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
Artal Group sold 350,000 Global Blood Therapeutics, Inc. shares in Q4 2019, an estimated $17M.
Artal Group first reported a position in Global Blood Therapeutics, Inc. in Q2 2016 and held it in 10 quarters.
Artal Group's Global Blood Therapeutics, Inc. position peaked at $17M in Q3 2019.
234 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2019.

Based on Artal Group's 13F filing for Q4 2019, filed 13 Feb 2020.